Document Detail

Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
MedLine Citation:
PMID:  24459196     Owner:  NLM     Status:  Publisher    
BACKGROUND: The aim of this study was to compare the safety and efficacy of biodegradable-polymer (BP) drug-eluting stents (DES), bare metal stents (BMS), and durable-polymer DES in patients undergoing coronary revascularization, we performed a systematic review and network meta-analysis using a Bayesian framework.
METHODS AND RESULTS: Study stents included BMS, paclitaxel-eluting (PES), sirolimus-eluting (SES), endeavor zotarolimus-eluting (ZES-E), cobalt-chromium everolimus-eluting (CoCr-EES), platinium-chromium everolimus-eluting (PtCr-EES), resolute zotarolimus-eluting (ZES-R), and BP biolimus-eluting stents (BP-BES). After a systematic electronic search, 113 trials with 90 584 patients were selected. The principal endpoint was definite or probable stent thrombosis (ST) defined according to the Academic Research Consortium within 1 year.
RESULTS: Biodegradable polymer-biolimus-eluting stents [OR, 0.56; 95% credible interval (CrI), 0.33-0.90], SES (OR, 0.53; 95% CrI, 0.38-0.73), CoCr-EES (OR, 0.34; 95% CrI, 0.23-0.52), and PtCr-EES (OR, 0.31; 95% CrI, 0.10-0.90) were all superior to BMS in terms of definite or probable ST within 1 year. Cobalt-chromium everolimus-eluting stents demonstrated the lowest risk of ST of all stents at all times after stent implantation. Biodegradable polymer-biolimus-eluting stents was associated with a higher risk of definite or probable ST than CoCr-EES (OR, 1.72; 95% CrI, 1.04-2.98). All DES reduced the need for repeat revascularization, and all but PES reduced the risk of myocardial infarction compared with BMS.
CONCLUSIONS: All DESs but PES and ZES-E were superior to BMS in terms of ST within 1 year. Cobalt-chromium everolimus-eluting stents was safer than any DES even including BP-BES. Our results suggest that not only the biodegradability of polymer, but the optimal combination of stent alloy, design, strut thickness, polymer, and drug all combined determine the safety of DES.
Si-Hyuck Kang; Kyung Woo Park; Do-Yoon Kang; Woo-Hyun Lim; Kyung Taek Park; Jung-Kyu Han; Hyun-Jae Kang; Bon-Kwon Koo; Byung-Hee Oh; Young-Bae Park; David E Kandzari; David J Cohen; Seung-Sik Hwang; Hyo-Soo Kim
Related Documents :
17533526 - Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after...
9259906 - Perinatal myocardial infarction in a newborn with a structurally normal heart.
22927556 - Stenting technique, gender, and age are associated with cardioprotection by ischaemic p...
8712136 - Influence of age on the prognostic importance of left ventricular dysfunction and conge...
18427646 - Evaluation of left ventricular long-axis function in cases of rheumatic pure mitral ste...
8100476 - Antifibrillatory effects of alpha 1-adrenoceptor blocking drugs in experimental coronar...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-1-23
Journal Detail:
Title:  European heart journal     Volume:  -     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Strategy of Daiichi Sankyo Discovery Research in Oncology.
Next Document:  Central blood pressure: current evidence and clinical importance.